Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study

Emilio Bria, Maria Vittoria Dieci, Valentina Guarneri, Fable Zustovich, Marta Mion, Paolo Morandi, Laura Merlini, Pierluigi Bullian, Cristina Oliani, Stefania Gori, Tommaso Giarratano, Enrico Orvieto, Gaia Griguolo, Silvia Michieletto, Tania Saibene, Paola Del Bianco, Gian Luca De Salvo, Pierfranco Conte

Risultato della ricerca: Contributo in rivistaArticolo in rivista

7 Citazioni (Scopus)

Fingerprint

Entra nei temi di ricerca di 'Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study'. Insieme formano una fingerprint unica.

Medicine & Life Sciences